Probable ribonuclease ZC3H12D (ZC3H12D)

Probable ribonuclease ZC3H12D (ZC3H12D) is an RNA-binding protein and putative exonuclease of the ZC3H12 family, characterized by a CCCH-type zinc finger domain and primarily localized in the cytoplasm, often in association with mRNA-processing bodies[2][3][5][7]. ZC3H12D negatively regulates cell proliferation and inflammatory signaling pathways by degrading specific target RNAs, such as cytokine mRNAs including IL-6, thereby dampening JNK, ERK, and NF-κB signaling and controlling macrophage activation[2][3][5][7]. It is highly expressed in immune tissues (spleen, lymph nodes, lung) and exerts tumor-suppressive effects in certain hematologic cancers and some solid tumors, e.g., by inhibiting the G1/S cell cycle transition[1][2][3]. Moreover, its expression influences immune cell differentiation, activation, and tumor immune microenvironment, with both high and low expression linked to differential tumor growth, cell motility, and patient prognosis. ZC3H12D may serve as a prognostic biomarker in cancer (notably lung adenocarcinoma) and plays dual roles in both inflammation and cancer biology, acting as a negative regulator within cytokine and immune signaling networks[1][2][3][7].

Other names

C6orf95MCPIP4TFLdJ281H8.1p34MCP-induced protein 4Transformed follicular lymphomaZinc finger CCCH domain-containing protein 12Dtumor suppressor TFLhZC3H12DZC3H12DpA2A288B7ZBA4

Drugs (if any were identified) modulating ZC3H12D would likely act by affecting RNA degradation, cytokine mRNA stability, or inflammatory signaling, but no specific drugs are directly documented targeting ZC3H12D in current sources[2][5][7].